Adherence to medical treatment for Wilson's disease in children and adolescents: a cohort study from Turkey.
Anxiety
Depression
Medication adherence
Quality of life
Wilson disease
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
11
09
2023
accepted:
03
03
2024
medline:
11
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
epublish
Résumé
This study aimed to assess medication adherence and demographic, clinical, and psychopathological parameters such as quality of life, depression, and anxiety levels that can affect pediatrics with Wilson's Disease (WD). A prospective cohort study was conducted at an outpatient clinic in Turkey among pediatric patients (2 to 18 years) with WD between November 2022 and April 2023. The Medication Adherence Report Scale (MARS-5) as a subjective and Medication Possession Ratio (MPR) as an objective assessment were scored. Physical, genetic and biochemical parameters, the Pediatric Quality of Life Inventory (PedsQL) for both parents and patients, Childhood Depression Inventory, State Trait Anxiety Inventory were also administered. A total of 30 pediatric outpatients who were prescribed D-penicillamine (n = 27) or trientine (n = 3) as chelators and zinc (n = 29) and pyridoxine (n = 19) as supplements were included. Proteinuria (n = 3), skin rash (n = 2), and gastrointestinal upset (n = 2) were observed. When the correlation between MARS-5 and duration of follow-up was examined, a significant negative correlation was found (p = 0.014). According to MPRs, non-adherence rates (missed doses ≥ 20%) were 29.6%, 17.2% and 5.3% for D-penicillamine, zinc and pyridoxine, respectively. PedsQL scores were higher than those of parents, with a positive correlation between them (p < 0.001). Also, there was a significant positive correlation between PedsQL and State Anxiety Inventory (p < 0.001). Comparing the change in urinary copper levels between different levels of treatment knowledge, significant differences were observed between high- and low levels (p = 0.043). Overall, nonadherence rates were 23.3% based on MARS-5 and 5.3-29.6% based on MPR. It is essential to consider factors such as the duration of follow-up, biochemical parameters, treatment knowledge, quality of life and anxiety as potential influencers of medication adherence.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to assess medication adherence and demographic, clinical, and psychopathological parameters such as quality of life, depression, and anxiety levels that can affect pediatrics with Wilson's Disease (WD).
METHODS
METHODS
A prospective cohort study was conducted at an outpatient clinic in Turkey among pediatric patients (2 to 18 years) with WD between November 2022 and April 2023. The Medication Adherence Report Scale (MARS-5) as a subjective and Medication Possession Ratio (MPR) as an objective assessment were scored. Physical, genetic and biochemical parameters, the Pediatric Quality of Life Inventory (PedsQL) for both parents and patients, Childhood Depression Inventory, State Trait Anxiety Inventory were also administered.
RESULTS
RESULTS
A total of 30 pediatric outpatients who were prescribed D-penicillamine (n = 27) or trientine (n = 3) as chelators and zinc (n = 29) and pyridoxine (n = 19) as supplements were included. Proteinuria (n = 3), skin rash (n = 2), and gastrointestinal upset (n = 2) were observed. When the correlation between MARS-5 and duration of follow-up was examined, a significant negative correlation was found (p = 0.014). According to MPRs, non-adherence rates (missed doses ≥ 20%) were 29.6%, 17.2% and 5.3% for D-penicillamine, zinc and pyridoxine, respectively. PedsQL scores were higher than those of parents, with a positive correlation between them (p < 0.001). Also, there was a significant positive correlation between PedsQL and State Anxiety Inventory (p < 0.001). Comparing the change in urinary copper levels between different levels of treatment knowledge, significant differences were observed between high- and low levels (p = 0.043).
CONCLUSIONS
CONCLUSIONS
Overall, nonadherence rates were 23.3% based on MARS-5 and 5.3-29.6% based on MPR. It is essential to consider factors such as the duration of follow-up, biochemical parameters, treatment knowledge, quality of life and anxiety as potential influencers of medication adherence.
Identifiants
pubmed: 38454433
doi: 10.1186/s13023-024-03113-0
pii: 10.1186/s13023-024-03113-0
pmc: PMC10921804
doi:
Substances chimiques
Penicillamine
GNN1DV99GX
Pyridoxine
KV2JZ1BI6Z
Zinc
J41CSQ7QDS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105Informations de copyright
© 2024. The Author(s).
Références
Hepatology. 2008 Jun;47(6):2089-111
pubmed: 18506894
BMC Neurol. 2019 Nov 12;19(1):278
pubmed: 31718567
Orphanet J Rare Dis. 2014 Mar 25;9:41
pubmed: 24661374
Am J Public Health. 2007 Oct;97(10):1756-7
pubmed: 17895405
Handb Clin Neurol. 2017;142:141-156
pubmed: 28433098
Qual Life Res. 2019 Nov;28(11):3107-3116
pubmed: 31230167
J Clin Psychol Med Settings. 2020 Mar;27(1):173-181
pubmed: 31127422
PLoS One. 2013 Jul 18;8(7):e69060
pubmed: 23874868
J Inherit Metab Dis. 2021 Nov;44(6):1481-1488
pubmed: 34480375
Psychiatry Investig. 2015 Jan;12(1):23-8
pubmed: 25670942
J Clin Exp Hepatol. 2023 Jan-Feb;13(1):22-30
pubmed: 36647409
J Pediatr Gastroenterol Nutr. 2007 May;44(5):596-602
pubmed: 17460493
J Clin Exp Hepatol. 2023 Jan-Feb;13(1):3-6
pubmed: 36647410
Pediatr Nurs. 2008 Mar-Apr;34(2):141-6
pubmed: 18543839
Int Rev Psychiatry. 2017 Oct;29(5):445-462
pubmed: 28681670
Dig Dis Sci. 2015 May;60(5):1433-9
pubmed: 25605552
Transl Neurodegener. 2012 Nov 27;1(1):23
pubmed: 23210912
Neurol Neurochir Pol. 2010 May-Jun;44(3):260-3
pubmed: 20625962
Saudi J Gastroenterol. 2022 Jan-Feb;28(1):21-31
pubmed: 35042319
Clin Res Hepatol Gastroenterol. 2022 Nov;46(9):101978
pubmed: 35714901